Middle East Liquid Embolic Agent Market Size, Share & Trends Analysis By Product Type (Ethylene Vinyl Alcohol Copolymer (EVOH), Cyanoacrylates), By Application, By End Use, By Country, And Segment Forecasts, 2025 - 2033
Description
Middle East Liquid Embolic Agent Market Summary
The Middle East liquid embolic agent market size was estimated at USD 8.08 million in 2024 and is projected to reach USD 10.92 million by 2033, growing at a CAGR of 3.13% from 2025 to 2033. The Middle East liquid embolic agent market is primarily driven by advancements in minimally invasive procedures and the increasing prevalence of vascular diseases.
As healthcare systems shift towards less invasive techniques, the demand for embolization agents used in treating conditions such as aneurysms, arteriovenous malformations (AVMs), and tumors has surged. The rise in prevalence of neurovascular and oncological disorders such as stroke, brain aneurysms, and cancers, many of which require embolization therapies. As the population ages and lifestyle-related diseases become more common, demand for effective, targeted treatments to manage complex vascular issues is growing. Liquid embolic agents are particularly effective in such scenarios, increasing their usage in neurovascular and oncological procedures. According to an article published in Galadari Printing and Publishing LLC and the Sheikh Khalifa Stroke Institute (SKSI), doctors are raising concerns over the rising number of younger stroke patients in the UAE, with an estimated 9,000 to 12,000 residents suffering a stroke each year. Alarmingly, around half of these cases occur in individuals under the age of 45-approximately 20 years younger than the global average age of 65.
“Stoke, however, is preventable. Individuals who get strokes usually suffer with sudden onset of limb weakness, speech difficulty, or difficulty in finding words, and an inability to use their hand or legs. If the patient arrives at the hospital or stroke center within the window period of four and half hours, the clot can be dissolved using medicines, commonly known as clot busters,” Dr Sandeep Burathoki, consultant interventional radiologist at International Modern Hospital Dubai, told Khaleej Times.
As liquid embolic agents are also used in minimally invasive cancer treatment to block blood flow to tumors for its growth inhibition, the growing cancer cases is also expected to fuel market growth over the forecast period. For instance, the graph below shows cancer mortality for both sexes, including non-melanoma skin cancer, in select Gulf countries as of 2022. Among these, Saudi Arabia reported the highest number of cancer-related deaths at 13,399, reflecting its larger population and increasing burden of non-communicable diseases.
Increasing investment in healthcare is a key driver of the Middle East liquid embolic agent market, particularly for advanced treatment areas such as interventional radiology and liquid embolic agents. Governments across the region, especially in Gulf countries such as Saudi Arabia, the UAE, and Kuwait, are significantly expanding healthcare budgets to modernize infrastructure, improve patient outcomes, and reduce reliance on overseas treatment. These investments fuel the construction of new hospitals, upgrading specialized departments, and procuring advanced medical technologies. As a result, there is a growing demand for minimally invasive therapies that are safer, faster, and more cost-effective-such as those involving liquid embolic agents for treating conditions such as arteriovenous malformations and cerebral aneurysms. Moreover, healthcare privatization and public-private partnerships are opening the market to international medical device manufacturers, further accelerating access to innovative embolization products. This trend is enhancing local health systems' capacity and positioning the Middle East as an emerging hub for high-end medical care in the broader region. According to the International Trade Administration, as of September 2024, the Kuwaiti government allocated USD 10 billion to its healthcare sector for the 2024/2025 budget, representing 11% of the total national budget. Of this amount, USD 608 million is dedicated to healthcare infrastructure, including plans to build and expand 10 hospitals over the next five years, while USD 56 million is allocated to support digital transformation initiatives within the sector.
Middle East Liquid Embolic Agent Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East liquid embolic agent market report based on product type, application, end use, and country:
The Middle East liquid embolic agent market size was estimated at USD 8.08 million in 2024 and is projected to reach USD 10.92 million by 2033, growing at a CAGR of 3.13% from 2025 to 2033. The Middle East liquid embolic agent market is primarily driven by advancements in minimally invasive procedures and the increasing prevalence of vascular diseases.
As healthcare systems shift towards less invasive techniques, the demand for embolization agents used in treating conditions such as aneurysms, arteriovenous malformations (AVMs), and tumors has surged. The rise in prevalence of neurovascular and oncological disorders such as stroke, brain aneurysms, and cancers, many of which require embolization therapies. As the population ages and lifestyle-related diseases become more common, demand for effective, targeted treatments to manage complex vascular issues is growing. Liquid embolic agents are particularly effective in such scenarios, increasing their usage in neurovascular and oncological procedures. According to an article published in Galadari Printing and Publishing LLC and the Sheikh Khalifa Stroke Institute (SKSI), doctors are raising concerns over the rising number of younger stroke patients in the UAE, with an estimated 9,000 to 12,000 residents suffering a stroke each year. Alarmingly, around half of these cases occur in individuals under the age of 45-approximately 20 years younger than the global average age of 65.
“Stoke, however, is preventable. Individuals who get strokes usually suffer with sudden onset of limb weakness, speech difficulty, or difficulty in finding words, and an inability to use their hand or legs. If the patient arrives at the hospital or stroke center within the window period of four and half hours, the clot can be dissolved using medicines, commonly known as clot busters,” Dr Sandeep Burathoki, consultant interventional radiologist at International Modern Hospital Dubai, told Khaleej Times.
As liquid embolic agents are also used in minimally invasive cancer treatment to block blood flow to tumors for its growth inhibition, the growing cancer cases is also expected to fuel market growth over the forecast period. For instance, the graph below shows cancer mortality for both sexes, including non-melanoma skin cancer, in select Gulf countries as of 2022. Among these, Saudi Arabia reported the highest number of cancer-related deaths at 13,399, reflecting its larger population and increasing burden of non-communicable diseases.
Increasing investment in healthcare is a key driver of the Middle East liquid embolic agent market, particularly for advanced treatment areas such as interventional radiology and liquid embolic agents. Governments across the region, especially in Gulf countries such as Saudi Arabia, the UAE, and Kuwait, are significantly expanding healthcare budgets to modernize infrastructure, improve patient outcomes, and reduce reliance on overseas treatment. These investments fuel the construction of new hospitals, upgrading specialized departments, and procuring advanced medical technologies. As a result, there is a growing demand for minimally invasive therapies that are safer, faster, and more cost-effective-such as those involving liquid embolic agents for treating conditions such as arteriovenous malformations and cerebral aneurysms. Moreover, healthcare privatization and public-private partnerships are opening the market to international medical device manufacturers, further accelerating access to innovative embolization products. This trend is enhancing local health systems' capacity and positioning the Middle East as an emerging hub for high-end medical care in the broader region. According to the International Trade Administration, as of September 2024, the Kuwaiti government allocated USD 10 billion to its healthcare sector for the 2024/2025 budget, representing 11% of the total national budget. Of this amount, USD 608 million is dedicated to healthcare infrastructure, including plans to build and expand 10 hospitals over the next five years, while USD 56 million is allocated to support digital transformation initiatives within the sector.
Middle East Liquid Embolic Agent Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East liquid embolic agent market report based on product type, application, end use, and country:
- Product Type Outlook (Revenue, USD Million, 2021 - 2033)
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- Cyanoacrylates
- N-BCA (n-Butyl Cyanoacrylate)
- N-HCA (n-Hexyl Cyanoacrylate)
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Arteriovenous Malformations (AVM)
- Hypervascular Tumors
- Peripheral Vasculature Hemorrhage
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Others
- Country Outlook (Revenue, USD Million, 2021 - 2033)
- Middle East
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product Type
- 1.1.2. Application
- 1.1.3. End Use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR’s internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Middle East Liquid Embolic Agent Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising prevalence of vascular diseases
- 3.2.1.2. Advancements in embolization technologies
- 3.2.1.3. Growing preference for minimally invasive procedures
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of agents and materials
- 3.2.2.2. Risk of complications and adverse events
- 3.2.2.3. Availability of alternative treatments
- 3.2.3. Market Opportunities Analysis
- 3.2.3.1. Technological innovations
- 3.2.3.2. Growing number of clinical trials
- 3.2.3.3. Expanding application areas
- 3.2.4. Market Challenge Analysis
- 3.2.4.1. Regulatory and approval barriers
- 3.3. Middle East Liquid Embolic Agent Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political & Legal Landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
- Chapter 4. Middle East Liquid Embolic Agent Market: Product Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Middle East Liquid Embolic Agent Market Movement Analysis
- 4.3. Middle East Liquid Embolic Agent Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
- 4.4. Ethylene Vinyl Alcohol Copolymer (EVOH)
- 4.4.1. Ethylene Vinyl Alcohol Copolymer (EVOH) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Cyanoacrylates
- 4.5.1. Cyanoacrylates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.1.1. N-BCA (n-Butyl Cyanoacrylate)
- 4.5.1.1.1. N-BCA (n-Butyl Cyanoacrylate) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.1.2. N-HCA (n-Hexyl Cyanoacrylate)
- 4.5.1.2.1. N-HCA (n-Hexyl Cyanoacrylate) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Others
- 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Middle East Liquid Embolic Agent Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Middle East Liquid Embolic Agent Market Movement Analysis
- 5.3. Middle East Liquid Embolic Agent Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 5.4. Arteriovenous Malformations (AVM)
- 5.4.1. Arteriovenous Malformations (AVM) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Hypervascular Tumors
- 5.5.1. Hypervascular Tumors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Peripheral Vasculature Hemorrhage
- 5.6.1. Peripheral Vasculature Hemorrhage Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Others
- 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Middle East Liquid Embolic Agent Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Middle East Liquid Embolic Agent Market Movement Analysis
- 6.3. Middle East Liquid Embolic Agent Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 6.4. Hospitals
- 6.4.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Specialty Clinics
- 6.5.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Ambulatory Surgical Centers (ASCs)
- 6.6.1. Ambulatory Surgical Centers (ASCs) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Others
- 6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Middle East Liquid Embolic Agent Market: Regional Estimates & Trend Analysis By Product Type, By Application, By End Use
- 7.1. Country Dashboard
- 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
- 7.3. Middle East
- 7.3.1. Middle East Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. Saudi Arabia
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Scenario
- 7.3.2.4. Reimbursement Scenario
- 7.3.2.5. Saudi Arabia Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. UAE
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Scenario
- 7.3.3.4. Reimbursement Scenario
- 7.3.3.5. UAE Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Kuwait
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Regulatory Scenario
- 7.3.4.4. Reimbursement Scenario
- 7.3.4.5. Kuwait Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.5. Oman
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Competitive Scenario
- 7.3.5.3. Regulatory Scenario
- 7.3.5.4. Reimbursement Scenario
- 7.3.5.5. Oman Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.6. Qatar
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Competitive Scenario
- 7.3.6.3. Regulatory Scenario
- 7.3.6.4. Reimbursement Scenario
- 7.3.6.5. Qatar Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.2.1. Innovators
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2024
- 8.3.4. Medtronic
- 8.3.4.1. Company Overview
- 8.3.4.2. Financial Performance
- 8.3.4.3. Service Benchmarking
- 8.3.4.4. Strategic Initiatives
- 8.3.5. B. Braun SE
- 8.3.5.1. Company Overview
- 8.3.5.2. Financial Performance
- 8.3.5.3. Product Benchmarking
- 8.3.5.4. Strategic Initiatives
- 8.3.6. Terumo
- 8.3.6.1. Company Overview
- 8.3.6.2. Financial Performance
- 8.3.6.3. Product Benchmarking
- 8.3.6.4. Strategic Initiatives
- 8.3.7. Meril
- 8.3.7.1. Company Overview
- 8.3.7.2. Financial Performance
- 8.3.7.3. Product Benchmarking
- 8.3.7.4. Strategic Initiatives
- 8.3.8. Gem srl
- 8.3.8.1. Company Overview
- 8.3.8.2. Financial Performance
- 8.3.8.3. Product Benchmarking
- 8.3.8.4. Strategic Initiatives
- 8.4. Heat Map Analysis/ Company Market Position Analysis
- 8.5. Estimated Company Market Share Analysis, 2024
- 8.6. List of Other Key Market Players
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
